Navigation Links
FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
Date:9/3/2007

About smallpox

Smallpox is a highly contagious disease caused by the variola virus, a member of the Orthopox virus family. It is one of the most devastating diseases known to humanity, with a mortality rate as high as 30%. In 1967, the World Health Organization embarked upon an intensified vaccination campaign to eliminate smallpox, which culminated in the successful eradication of the disease globally by 1980.(1)

By the mid-1980s, there were only two known repositories of variola virus: the Institute of Virus Preparations in Russia, and the US CDC. The events in the US in September and October 2001 highlighted the risk that the variola virus might be used as an agent of bioterrorism.(2) Governments around the world are taking precautionary measures to be ready to deal with a potential smallpox outbreak.

About ACAM2000

- ACAM2000 is a live, vaccinia virus smallpox vaccine indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.

- It is a single-dose vaccine administered percutaneously.

- It was derived by plaque purification from Dryvax(R), the licensed calf lymph-produced vaccine that was extensively used in the smallpox eradication program.

- ACAM2000 is manufactured in Vero cells using modern cell-culture techniques designed to comply with current Good Manufacturing Practice standards.

- Acambis has supplied more than 200 million doses of ACAM2000 under an FDA Investigational New Drug application to 15 governments around the world, including the US.

Notes and references

(1) WHO: http://www.who.int/mediacentre/factsheets/smallpox/en/

(2) CDC: http://www.bt.cdc.gov/agent/smallpox/overview/disease-facts.asp

About Acambis

Acambis is a leading vaccin
'/>"/>

SOURCE Acambis plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Mexico firm to make flu vaccine at Wisconsin BioManufacturing facility
9. Studies Offer New Insight into HIV Vaccine Development
10. Protector RNase Inhibitor Enhance the Protection of RNA against Degradation
11. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... to video screens, Eau Claire-based entrepreneur Mike Strand ... , ,A former technology consultant for Delta Technology and Cray ... founded StrandWare Inc. , a company based out of ... sold the company in 2001, it had expanded into a ...
... Income from continuing operations at Milwaukee-based Rockwell Automation Inc. for ... 90 percent leap from the $74.9 million the company earned ... quarter of 2005, including discontinued operations, was an even $150 ... that, Rockwell shares fell off the table, dropping more than ...
... the British Consulate-General, which is looking to expand ... companies on Tuesday for a luncheon to explore ... with complimentary products or complimentary technologies," said Frank ... of the British Consulate-General . "Oftentimes the partnership ...
Cached Biology Technology:Online Kiosks founder Mike Strand uses contest to screen new business plan 2Online Kiosks founder Mike Strand uses contest to screen new business plan 3British, Wisconsin firms explore life-science opportunities together 2British, Wisconsin firms explore life-science opportunities together 3
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... the Journal of Antimicrobial Chemotherapy1 provides the best ... (CDI)---one of the most common and increasing types ... if doctors prescribe narrow-spectrum antibiotics rather than broad-spectrum ... Hospital in London, which now has the lowest ...
... plays a major role in deadly prion diseases by ... "seeds" that allow fatal brain illnesses to quickly spread, ... exciting, researchers say, because they might reveal a way ... If a drug could be made that inhibits this ...
... bird flu, involving the use of a mathematical model, ... be the best way to deal with an emerging ... a worldwide human epidemic yet because it rarely passes ... would take 6-8 months to develop a vaccine effective ...
Cached Biology News:Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates 2Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates 3Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates 4Brown team finds crucial protein role in deadly prion spread 2
Sf21 Insect Cells (Frozen) in Max-XP Medium...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
Biology Products: